Cannabis manufacturers are in the starting blocks.
In two months, a first experiment with medical cannabis will start in France.
It will make it possible to provide, free of charge, and on prescription, 3000 patients suffering from serious illnesses (certain forms of epilepsy, neuropathic pain, side effects of chemotherapy, palliative care or multiple sclerosis) in a situation of treatment failure, either because of insufficient relief, or because of poor tolerance of existing drugs.
Pharmacies will be at the heart of the system.
The National Medicines Safety Agency (ANSM) has just unveiled the list of six suppliers selected as part of a call for tenders launched in the fall.
Each manufacturer won a market segment, in tandem with a distributor based in France.
Alongside the Canadian heavyweights, Aurora (dried cannabis flowers) and Tilray (oil), are the Israeli Panaxia (capsules) and the Australian Little
This article is for subscribers only.
You have 75% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT